Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Celtics Live

109

102

Final

Cellceutix enters into a collaborative agreement with Beth Israel Deaconess

Cellceutix Corp., a Beverly biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, said it plans to collaborate with Beth Israel Deaconess Medical Center on a research project that will explore the potential of a Cellceutix drug candidate for treating certain types of cancer.

According to Cellceutix, Beth Israel wants to look into the the nuclear and mitochondrial pro-apoptotic function of p53 in melanoma and renal cell carcinoma, two types of cancer that are particularly resistant to therapy.

Continue reading below

The p53 signaling pathway is a crucial regulator of cell cycle and apoptosis.

On its website, Cellceutix says that its drug candidate Kevetrin has “demonstrated the potential for a major breakthrough in cancer research by exhibiting an activation of p53.”

The collaborative studies are independent from the planned clinical trials for Kevetrin, Cellceutix said in a press release.

In a statement, Cellceutix chief executive Leo Ehrlich said: “Beth Israel Deaconess Medical Center will be researching Kevetrin for indications in addition to those which we will be studying in our company-sponsored clinical trials. If they collect promising data in their research of Kevetrin in melanoma and renal cell carcinoma, additional grant and government funding may become available to further study these separate indications, saving us substantial time and money towards the end goal of commercialization.”

Chris Reidy can be reached at reidy@globe.com.
Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week